Structure-Property Optimization of a Series of Imidazopyridines for Visceral Leishmaniasis.

"The authors declare no competing financial interest."

"The authors acknowledge funding from the National Institute of Allergy and Infectious Diseases (M.P.P. R33AI141227) and Sao Paulo Research Foundation (grant # 2021/11899-0 and grant #2017/21146-4). We thank AstraZeneca, and Charles River Laboratories for the provision of the in vitro ADME and physicochemical properties data included in the manuscript. We would like to acknowledge Professor Roman Manetsch’s lab at Northeastern University for allowing us ad hoc access to their LCMS system. Use of JChem/ChemAxon software (Product version 20.11.0, ChemAxon (https://www.chemaxon.com)) is acknowledged. We acknowledge support from the Major Research Instrumentation (MRI) Program of the National Science Foundation under NSF award no. 2216066 for the X-ray facility. DNDi thanks the following donors for funding the Drug Discovery Booster: Federal Ministry of Education and Research (BMBF) through KfW, Germany; Global Health Innovative Technology Fund (GHIT Fund), Japan; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands. DNDi also thanks UK aid, UK; Médecins Sans Frontières International and the Swiss Agency for Development and Cooperation (SDC), Switzerland, for funding its overall mission."